Constructing vascularized hepatic tissue by cell-assembled viscous tissue sedimentation method and its application for vascular toxicity assessment
Source abstract
Abstract
In vitro Construction of the liver sinusoidal structure using artificial tissue is an important but worthwhile challenge, particularly for assessing the risk of diseases such as sinusoidal obstruction syndrome (SOS). Current models are unsuitable for evaluating the toxicity because of lacking sinusoidal capillary. In this study, we developed a vascularized hepatic tissue (VHT) using a unique tissue engineering technique, the cell assembled viscous tissue by sedimentation (CAViTs) method. The "viscous bodies" created using the CAViTs method exhibited significant self-assembly within 6 h after seeding, promoting cell-cell interaction. The level of albumin secreted by the VHT was four times higher than that of 2D-coculture and maintained for 1 month. The gene expression pattern of the VHT was closer to that of total human liver, compared with the 2D system. Quantitative evaluations of the vascular structure of VHT treated with two typical SOS-inducing compounds, monocrotaline and retrorsine, revealed higher sensitivity (IC50 = 40.35 µM), 19.92 times higher than the cell-viability assay. Thus, VHT represents an innovative in vitro model that mimics the vessel network structure and could become a useful tool for the early screening of compounds associated with a risk of vascular toxicity. STATEMENT OF SIGNIFICANCE: Mimicking sinusoidal structures in in vitro liver model is important to consider from the perspective of predicting hepatotoxicity such like sinusoidal obstruction syndrome (SOS). However, it was difficult to reconstruct the vascular structure within the hepatocyte-rich environment. In this study, we constructed a vascularized hepatic tissue in a high-throughput manner by a unique method using collagen and heparin, and evaluated its applicability to toxicity assessment. Vessel morphology analysis of the model treated by monocrotaline, which is a well-known SOS-inducing compound, could predict the toxicity with higher sensitivity. To the best of our knowledge, this is the first report to provide vascularized hepatic tissues using sinusoidal endothelial cells at least for demonstrating applicability to the evaluation of SOS induction risk.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Liver physiology and pathology · Proteoglycans and glycosaminoglycans research · 3D Printing in Biomedical Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (62)
Show source-provided references
1. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models10.1038/s41573-019-0048-x ↗
2. Models of drug induced liver injury (DILI)–current issues and future perspectives10.2174/1389200219666180523095355 ↗
3. Cell sources for in vitro human liver cell culture models10.1177/1535370216657448 ↗
4. Competency of different cell models to predict human hepatotoxic drugs10.1517/17425255.2014.967680 ↗
5. Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation10.1002/hep.28780 ↗
6. Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport10.1124/dmd.105.009118 ↗
7. Bile canaliculi formation and biliary transport in 3D sandwich-cultured hepatocytes in dependence of the extracellular matrix composition10.1007/s00204-016-1758-z ↗
8. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease10.1038/srep25187 ↗
9. Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability10.1038/srep35434 ↗
10. Microscale culture of human liver cells for drug development10.1038/nbt1361 ↗
11. Microscale collagen and fibroblast interactions enhance primary human hepatocyte functions in 3-dimensional models10.3727/105221620X15868728381608 ↗
12. Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans10.1093/toxsci/kfs326 ↗
13. Recent progress in hepatocyte culture models and their application to the assessment of drug metabolism, transport, and toxicity in drug discovery: the value of tissue engineering for the successful development of a microphysiological system10.1016/j.xphs.2017.05.010 ↗
14. Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration10.1021/bp00009a007 ↗
15. Three-dimensional (3D) printing of mouse primary hepatocytes to generate 3D hepatic structure10.4174/astr.2017.92.2.67 ↗
16. Characterization of a reproducible rat model of hepatic veno-occlusive disease10.1002/hep.510290615 ↗
17. Sinusoidal obstruction syndrome10.1016/j.clinre.2016.01.006 ↗
18. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes10.3748/wjg.v25.i28.3753 ↗
19. Species differences in the response of liver drug-metabolizing enzymes to (S)-4-O-tolylsulfanyl-2-(4-trifluormethyl-phenoxy)-butyric acid (EMD 392949) in vivo and in vitro10.1124/dmd.107.018358 ↗
20. 3D liver membrane system by co-culturing human hepatocytes, sinusoidal endothelial and stellate cells10.1088/1758-5090/aa70c7 ↗
21. Fabrication of functional 3D hepatic tissues with polarized hepatocytes by stacking endothelial cell sheets in vitro10.1002/term.2102 ↗
22. Construction of three-dimensional vascularized functional human liver tissue using a layer-by-layer cell coating technique10.1016/j.biomaterials.2017.02.034 ↗
23. Microengineered cell and tissue systems for drug screening and toxicology applications: evolution of in-vitro liver technologies
24. Construction of three-dimensional liver tissue models by cell accumulation technique and maintaining their metabolic functions for long-term culture without medium change10.1002/jbm.a.35292 ↗
25. Development of vascularized iPSC derived 3D-cardiomyocyte tissues by filtration Layer-by-Layer technique and their application for pharmaceutical assays10.1016/j.actbio.2016.01.033 ↗
26. S. Kitano, S. Irie, M. Matsusaki, Cell viscous assembly methos, (2021).
27. In vitro evaluation of cytochrome P450 and glucuronidation activities in hepatocytes isolated from liver-humanized mice10.2133/dmpk.DMPK-10-RG-047 ↗
28. High-throughput screening to evaluate inhibition of bile acid transporters using human hepatocytes isolated from chimeric mice10.1093/toxsci/kfz229 ↗
29. Culture density contributes to hepatic functions of fresh human hepatocytes isolated from chimeric mice with humanized livers: novel, long-term, functional two-dimensional in vitro tool for developing new drugs10.1371/journal.pone.0237809 ↗
30. Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man10.1007/s00204-016-1845-1 ↗
31. Monocrotaline-induced liver toxicity in rat predicted by a combined in vitro physiologically based kinetic modeling approach10.1007/s00204-020-02798-z ↗
32. iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data10.1186/s12859-018-2486-6 ↗
33. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets10.1038/s41467-019-09234-6 ↗
34. Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury10.1007/s00204-017-2002-1 ↗
35. FDA-approved drug labeling for the study of drug-induced liver injury10.1016/j.drudis.2011.05.007 ↗
36. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans10.1016/j.drudis.2016.02.015 ↗
37. NIH Image to ImageJ: 25 years of image analysis10.1038/nmeth.2089 ↗
38. Retinal blood vessel detection using wavelet-matched filter10.1117/1.OE.52.3.037204 ↗
39. Immunofluorescence identifies distinct subsets of endothelial cells in the human liver10.1038/srep44356 ↗
40. Setting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays10.1093/toxsci/kfv152 ↗
41. Characterization of a long-term mouse primary liver 3D tissue model recapitulating innate-immune responses and drug-induced liver toxicity10.1371/journal.pone.0235745 ↗
42. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy10.1038/sj.bjc.6603097 ↗
43. Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids10.1016/S0168-8278(03)00231-9 ↗
44. Heparin binding nanostructures to promote growth of blood vessels10.1021/nl0613555 ↗
45. The affinity of fibroblast growth factors (FGFs) for heparin; FGF-heparan sulfate interactions in cells and extracellular matrix10.1016/0955-0674(90)90084-R ↗
46. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis10.1083/jcb.141.7.1659 ↗
47. Interaction of vascular endothelial growth factor and heparin quantified by single molecule force spectroscopy10.1039/D0NR01570A ↗
48. A cell surface receptor complex for collagen type I recognizes the Arg-Gly-Asp sequence10.1083/jcb.104.3.585 ↗
49. Heparin-protein interactions10.1002/1521-3773(20020201)41:3<390::AID-ANIE390>3.0.CO;2-B ↗
50. Heparin: an intervenor in cell communication10.1111/j.1582-4934.2009.00871.x ↗
51. Cell–cell crosslinking by bio-molecular recognition of heparin-based layer-by-layer nanofilms10.1002/mabi.201400415 ↗
52. Hepatocyte polarity10.1002/j.2040-4603.2013.tb00490.x ↗
53. Long-term culture and coculture of primary rat and human hepatocytes10.1007/978-1-62703-125-7_17 ↗
54. Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation10.1111/cts.12969 ↗
55. Hepatic stellate cells and parasite-induced liver fibrosis10.1186/1756-3305-3-60 ↗
56. Comprehensive analysis of serum microRNAs in hepatic sinusoidal obstruction syndrome (SOS) in rats: implication as early phase biomarkers for SOS10.1007/s00204-018-2269-x ↗
57. Development of a two-layer transwell co-culture model for the in vitro investigation of pyrrolizidine alkaloid-induced hepatic sinusoidal damage10.1016/j.fct.2019.04.057 ↗
58. A simple procedure for determining the aqueous half-lives of pyrrolic metabolites of pyrrolizidine alkaloids10.1016/0041-0101(95)00169-7 ↗
59. Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes10.1016/j.bbmt.2013.04.005 ↗
60. The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis)10.1097/00001721-199707000-00003 ↗
61. Soluble thrombomodulin attenuates endothelial cell damage in hepatic sinusoidal obstruction syndrome10.21873/invivo.11393 ↗
62. Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation10.1038/s41409-018-0304-4 ↗